Empagliflozin shows efficacy as stand-alone diabetes treatment

10/4/2013 | Medscape (free registration)

Previously untreated type 2 diabetes patients who either took empagliflozin or sitagliptin showed greater improvements in A1C compared with a placebo group, according to a study in The Lancet Diabetes & Endocrinology. Patients in the empagliflozin arm also showed better fasting plasma glucose and greater reductions in weight, waist size and systolic blood pressure compared with the sitagliptin group, suggesting the drug is effective as monotherapy.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN